|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHMP1B |
Gene summary for CHMP1B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHMP1B | Gene ID | 57132 |
| Gene name | charged multivesicular body protein 1B | |
| Gene Alias | C10orf2 | |
| Cytomap | 18p11.21 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q7LBR1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57132 | CHMP1B | CCI_1 | Human | Cervix | CC | 1.94e-05 | -5.13e-01 | 0.528 |
| 57132 | CHMP1B | CCI_2 | Human | Cervix | CC | 7.14e-05 | -5.13e-01 | 0.5249 |
| 57132 | CHMP1B | CCI_3 | Human | Cervix | CC | 1.02e-07 | -5.13e-01 | 0.516 |
| 57132 | CHMP1B | CCII_1 | Human | Cervix | CC | 3.27e-11 | -5.13e-01 | 0.3249 |
| 57132 | CHMP1B | sample3 | Human | Cervix | CC | 6.56e-06 | -1.39e-01 | 0.1387 |
| 57132 | CHMP1B | T3 | Human | Cervix | CC | 8.96e-06 | -1.48e-01 | 0.1389 |
| 57132 | CHMP1B | HTA11_2487_2000001011 | Human | Colorectum | SER | 3.70e-09 | 2.41e-01 | -0.1808 |
| 57132 | CHMP1B | HTA11_1938_2000001011 | Human | Colorectum | AD | 3.43e-08 | 3.09e-01 | -0.0811 |
| 57132 | CHMP1B | HTA11_78_2000001011 | Human | Colorectum | AD | 2.48e-07 | 2.13e-01 | -0.1088 |
| 57132 | CHMP1B | HTA11_347_2000001011 | Human | Colorectum | AD | 1.02e-14 | 3.16e-01 | -0.1954 |
| 57132 | CHMP1B | HTA11_411_2000001011 | Human | Colorectum | SER | 1.20e-07 | 4.72e-01 | -0.2602 |
| 57132 | CHMP1B | HTA11_3361_2000001011 | Human | Colorectum | AD | 3.26e-04 | 1.69e-01 | -0.1207 |
| 57132 | CHMP1B | HTA11_696_2000001011 | Human | Colorectum | AD | 7.82e-13 | 2.36e-01 | -0.1464 |
| 57132 | CHMP1B | HTA11_866_2000001011 | Human | Colorectum | AD | 9.04e-05 | 1.23e-01 | -0.1001 |
| 57132 | CHMP1B | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.21e-08 | 2.25e-01 | -0.059 |
| 57132 | CHMP1B | HTA11_2992_2000001011 | Human | Colorectum | SER | 1.51e-04 | 2.63e-01 | -0.1706 |
| 57132 | CHMP1B | HTA11_5212_2000001011 | Human | Colorectum | AD | 2.28e-02 | 1.70e-01 | -0.2061 |
| 57132 | CHMP1B | HTA11_7862_2000001011 | Human | Colorectum | AD | 1.24e-02 | 1.79e-01 | -0.0179 |
| 57132 | CHMP1B | HTA11_866_3004761011 | Human | Colorectum | AD | 5.92e-06 | 1.66e-01 | 0.096 |
| 57132 | CHMP1B | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.58e-06 | 3.83e-01 | 0.0131 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001603210 | Cervix | CC | viral process | 109/2311 | 415/18723 | 5.40e-15 | 6.46e-12 | 109 |
| GO:001905810 | Cervix | CC | viral life cycle | 87/2311 | 317/18723 | 2.20e-13 | 1.20e-10 | 87 |
| GO:00516567 | Cervix | CC | establishment of organelle localization | 76/2311 | 390/18723 | 3.17e-05 | 5.21e-04 | 76 |
| GO:002241110 | Cervix | CC | cellular component disassembly | 83/2311 | 443/18723 | 6.04e-05 | 8.68e-04 | 83 |
| GO:00161977 | Cervix | CC | endosomal transport | 48/2311 | 230/18723 | 1.65e-04 | 1.97e-03 | 48 |
| GO:19021153 | Cervix | CC | regulation of organelle assembly | 40/2311 | 186/18723 | 2.92e-04 | 3.15e-03 | 40 |
| GO:00009107 | Cervix | CC | cytokinesis | 37/2311 | 173/18723 | 5.40e-04 | 5.23e-03 | 37 |
| GO:00070347 | Cervix | CC | vacuolar transport | 34/2311 | 157/18723 | 7.03e-04 | 6.40e-03 | 34 |
| GO:00705074 | Cervix | CC | regulation of microtubule cytoskeleton organization | 32/2311 | 148/18723 | 1.02e-03 | 8.51e-03 | 32 |
| GO:00160506 | Cervix | CC | vesicle organization | 54/2311 | 300/18723 | 2.71e-03 | 1.85e-02 | 54 |
| GO:00329847 | Cervix | CC | protein-containing complex disassembly | 41/2311 | 224/18723 | 6.13e-03 | 3.48e-02 | 41 |
| GO:01400143 | Cervix | CC | mitotic nuclear division | 50/2311 | 287/18723 | 7.27e-03 | 3.91e-02 | 50 |
| GO:00482851 | Cervix | CC | organelle fission | 78/2311 | 488/18723 | 9.70e-03 | 4.79e-02 | 78 |
| GO:0016032 | Colorectum | AD | viral process | 168/3918 | 415/18723 | 4.67e-20 | 3.66e-17 | 168 |
| GO:0019058 | Colorectum | AD | viral life cycle | 119/3918 | 317/18723 | 6.18e-12 | 8.23e-10 | 119 |
| GO:0016197 | Colorectum | AD | endosomal transport | 90/3918 | 230/18723 | 1.88e-10 | 1.73e-08 | 90 |
| GO:0022411 | Colorectum | AD | cellular component disassembly | 147/3918 | 443/18723 | 8.53e-10 | 6.76e-08 | 147 |
| GO:0051656 | Colorectum | AD | establishment of organelle localization | 131/3918 | 390/18723 | 3.00e-09 | 2.06e-07 | 131 |
| GO:0032984 | Colorectum | AD | protein-containing complex disassembly | 81/3918 | 224/18723 | 9.41e-08 | 4.65e-06 | 81 |
| GO:0016050 | Colorectum | AD | vesicle organization | 101/3918 | 300/18723 | 1.65e-07 | 7.17e-06 | 101 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0414418 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa0414419 | Cervix | CC | Endocytosis | 64/1267 | 251/8465 | 6.97e-06 | 6.10e-05 | 3.61e-05 | 64 |
| hsa04144 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041441 | Colorectum | AD | Endocytosis | 111/2092 | 251/8465 | 5.95e-12 | 1.42e-10 | 9.08e-11 | 111 |
| hsa041442 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa041443 | Colorectum | SER | Endocytosis | 81/1580 | 251/8465 | 1.14e-07 | 2.36e-06 | 1.71e-06 | 81 |
| hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa041444 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa041445 | Colorectum | MSS | Endocytosis | 102/1875 | 251/8465 | 1.85e-11 | 4.43e-10 | 2.71e-10 | 102 |
| hsa0414429 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144113 | Esophagus | HGIN | Endocytosis | 76/1383 | 251/8465 | 1.74e-08 | 3.34e-07 | 2.65e-07 | 76 |
| hsa04144210 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414437 | Esophagus | ESCC | Endocytosis | 186/4205 | 251/8465 | 9.74e-16 | 4.66e-14 | 2.39e-14 | 186 |
| hsa0414412 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414413 | Liver | Cirrhotic | Endocytosis | 119/2530 | 251/8465 | 2.33e-09 | 4.56e-08 | 2.81e-08 | 119 |
| hsa0414422 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414432 | Liver | HCC | Endocytosis | 178/4020 | 251/8465 | 2.03e-14 | 5.22e-13 | 2.91e-13 | 178 |
| hsa0414427 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| hsa04144112 | Oral cavity | OSCC | Endocytosis | 174/3704 | 251/8465 | 9.42e-17 | 4.51e-15 | 2.29e-15 | 174 |
| Page: 1 2 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHMP1B | SNV | Missense_Mutation | novel | c.481N>T | p.Gly161Cys | p.G161C | Q7LBR1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CHMP1B | SNV | Missense_Mutation | novel | c.107N>A | p.Ile36Asn | p.I36N | Q7LBR1 | protein_coding | deleterious(0) | benign(0.361) | TCGA-BH-AB28-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD |
| CHMP1B | insertion | In_Frame_Ins | novel | c.482_483insTAT | p.Gly161_Leu162insIle | p.G161_L162insI | Q7LBR1 | protein_coding | TCGA-A8-A09N-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| CHMP1B | SNV | Missense_Mutation | c.94N>A | p.Glu32Lys | p.E32K | Q7LBR1 | protein_coding | deleterious(0.02) | possibly_damaging(0.903) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | |
| CHMP1B | insertion | Frame_Shift_Ins | rs756274240 | c.72dupA | p.Cys25MetfsTer3 | p.C25Mfs*3 | Q7LBR1 | protein_coding | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| CHMP1B | SNV | Missense_Mutation | novel | c.195N>A | p.Phe65Leu | p.F65L | Q7LBR1 | protein_coding | tolerated(1) | possibly_damaging(0.506) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| CHMP1B | SNV | Missense_Mutation | novel | c.289A>G | p.Lys97Glu | p.K97E | Q7LBR1 | protein_coding | deleterious(0) | possibly_damaging(0.793) | TCGA-AX-A1C4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| CHMP1B | SNV | Missense_Mutation | novel | c.214N>C | p.Val72Leu | p.V72L | Q7LBR1 | protein_coding | tolerated(0.28) | benign(0.007) | TCGA-B5-A3FA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHMP1B | SNV | Missense_Mutation | c.256N>T | p.Gly86Cys | p.G86C | Q7LBR1 | protein_coding | deleterious(0) | possibly_damaging(0.762) | TCGA-BS-A0UL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| CHMP1B | SNV | Missense_Mutation | novel | c.195N>A | p.Phe65Leu | p.F65L | Q7LBR1 | protein_coding | tolerated(1) | possibly_damaging(0.506) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |